Citation

Coplan PM, Sessler NE, Harikrishnan V, Singh R, Perkel C. Postgrad. Med. 2016; 129(1): 55-61.

Affiliation

Mount Sinai Beth Israel , Bernstein Pavilion, 10 Nathan D Perlman Place, New York , NY 10003.

Copyright

(Copyright © 2016, Vendome Group)

DOI

10.1080/00325481.2017.1269596

PMID

27922764

Abstract

OBJECTIVE: Prescription opioid related abuse, suicide and death are significant public health problems. This study compares rates of poison center calls categorized as intentional abuse, suspected suicidal intent or fatality for the 7-day buprenorphine transdermal system/patch (BTDS) with other extended-release and long-acting (ER/LA) opioids indicated for chronic pain.

DESIGN: Retrospective 24-month cohort study using National Poison Data System data from July 2012 through June 2014. BTDS was introduced in the United States in January 2011.

METHODS: Numbers and rates of calls of intentional abuse, suspected suicidal intent and fatalities were evaluated for BTDS, ER morphine, ER oxycodone, fentanyl patch, ER oxymorphone and methadone tablets/capsules, using prescription adjustment to account for community availability. Rate ratios (RR) and 95% confidence intervals (CI) were calculated.

RESULTS: Absolute numbers and prescription-adjusted rates of intentional abuse and suspected suicidal intent with BTDS were significantly lower (p<.0001) than for all other ER/LA opioid analgesics examined. No fatalities associated with BTDS exposure were reported.

CONCLUSION: This post-marketing evaluation of BTDS indicates infrequent poison center calls for intentional abuse and suspected suicidal intent events, suggesting lower rates of these risks with BTDS compared to other ER/LA opioids.

Language: en